Valuation: Asahi Kasei Corporation

Capitalization 2,029B 12.83B 10.97B 10.18B 9.55B 17.72B 1,175B 18.97B 117B 46.24B 555B 48.11B 47.12B P/E ratio 2026 *
14.8x
P/E ratio 2027 * 12.5x
Enterprise value 2,841B 17.96B 15.36B 14.26B 13.37B 24.81B 1,645B 26.56B 164B 64.75B 778B 67.37B 65.99B EV / Sales 2026 *
0.92x
EV / Sales 2027 * 0.87x
Free-Float
95.58%
Yield 2026 *
2.71%
Yield 2027 * 2.97%
More valuation ratios * Estimated data
Dynamic Chart
01-08 Zoll Strengthens Growth Trajectory for Asahi Kasei's Healthcare Sector with U.S. Launch of the Next-Generation Lifevest®? Wcd CI
01-06 Tranche Update on Asahi Kasei Corporation's Equity Buyback Plan announced on November 5, 2025. CI
12-24 Asahi Yukizai Corp to spend 17.5 billion yen to build new production base in Miyazaki, Japan for precision valves for semiconductor manufacturing equipment RE
12-05 Asahi Kasei Strengthens Long-Term Profitability by Phasing Out HMD Production as Part of Structural Reform CI
12-05 Asahi Kasei Corp to discontinue production of hexamethylene diamine RE
12-02 Asahi Kasei accelerates portfolio transformation with divestiture of Daramic lead battery separator business RE
12-01 Kingswood Capital Management, LP acquired Daramic, LLC from Asahi Kasei Corporation. CI
12-01 SENSIL by NILIT and ROICA by Asahi Kasei Collaborate to Reduce Apparel?s Footprint CI
12-01 Asahi Kasei Advance and Teijin Frontier to integrate businesses, effective October 1, 2026 RE
11-30 Teijin Frontier Co., Ltd. concluded a basic agreement to acquire Asahi Kasei Advance Corporation from Asahi Kasei Corporation. CI
11-16 Asahi Kasei: Filed litigation for infringement of patent rights of Ceolus in China RE
11-12 Asahi Kasei Microdevices Showcases AgeTech and PetTech Solutions Combining Privacy and Convenience At CES 2026 CI
11-10 Calliditas Therapeutics Reports Safety Data for Setanaxib in Patients with Alport Syndrome At the American Society of Nephrology Kidney Week CI
More news
1 day+0.97%
1 week+1.00%
Current month+8.57%
1 month+8.92%
3 months+24.68%
6 months+49.98%
Current year+8.57%
More quotes
1 week 1,471
Extreme 1471
1,529.5
1 month 1,368
Extreme 1368
1,529.5
Current year 1,415
Extreme 1415
1,529.5
1 year 880
Extreme 880
1,529.5
3 years 880
Extreme 880
1,529.5
5 years 880
Extreme 880
1,529.5
10 years 606.1
Extreme 606.1
1,765
More quotes
Manager TitleAgeSince
President 66 2022-03-31
Chief Administrative Officer - -
Corporate Officer/Principal 60 2011-03-31
Director TitleAgeSince
Chairman 70 2022-03-31
Director/Board Member 78 2018-05-31
Director/Board Member 66 2021-05-31
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.97%+1.00%+45.56%+58.09% 12.83B
+2.95%+1.78%+9.54%+64.85% 65.02B
+2.39%+1.55%+2.02%-11.49% 46.79B
+2.18%-2.84%+5.67%+20.58% 15.8B
+2.18%-9.76%+6.21%+29.37% 8.66B
+2.12%+3.20%+28.66%+43.80% 8.57B
+0.82%+2.05%-1.54% - 8.7B
+2.20%-2.16%-9.54%-24.87% 8.37B
+0.50%-2.14%-0.50%-5.55% 5.5B
+1.73%+1.85%+25.03%+61.92% 4.94B
Average +1.83%-2.37%+11.11%+26.30% 18.52B
Weighted average by Cap. +2.37%-1.80%+9.26%+30.86%
See all sector performances

Financials

2026 *2027 *
Net sales 3,075B 19.45B 16.63B 15.43B 14.48B 26.86B 1,781B 28.76B 177B 70.1B 842B 72.93B 71.44B 3,198B 20.23B 17.29B 16.05B 15.05B 27.93B 1,853B 29.91B 184B 72.9B 876B 75.84B 74.29B
Net income 137B 866M 740M 687M 644M 1.2B 79.31B 1.28B 7.89B 3.12B 37.48B 3.25B 3.18B 161B 1.02B 871M 808M 758M 1.41B 93.26B 1.51B 9.27B 3.67B 44.08B 3.82B 3.74B
Net Debt 812B 5.14B 4.39B 4.08B 3.82B 7.09B 470B 7.59B 46.78B 18.51B 222B 19.26B 18.86B 769B 4.86B 4.16B 3.86B 3.62B 6.72B 445B 7.19B 44.3B 17.53B 211B 18.24B 17.87B
More financial data * Estimated data
Logo Asahi Kasei Corporation
Asahi Kasei Corp is a Japan-based company mainly engaged in the materials business, housing business and healthcare business. The Company operates through three business segments. The Materials segment provides styrene monomer, acrylonitrile, polyethylene, automotive-related fibers, electronic materials, mixed signal large scale integrated circuits (LSI), hall elements, deep ultraviolet light-emitting diodes (LEDs), pharmaceutical and food additives and others. The Housing segment provides construction contracting, renovation and other housing-related business, as well as lightweight aerated concrete (ALC), insulation materials and others. The Healthcare segment provides medical drugs, hemodialysis and apheresis related equipment, virus removal filters, cardiopulmonary resuscitation-related products and others. The Company also provides plant engineering, environmental engineering, various research and information provision businesses, and personnel dispatch and introduction services.
Employees
50,352
More about the company
Date Price Change Volume
26-01-22 1,508.00 ¥ +0.97% 3,729,100
26-01-21 1,493.50 ¥ +0.03% 3,267,000
26-01-20 1,493.00 ¥ -2.10% 4,390,300
26-01-19 1,525.00 ¥ +0.69% 5,028,400
26-01-16 1,514.50 ¥ +1.58% 5,108,300

Delayed Quote Japan Exchange, January 22, 2026 at 01:30 am

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1,493.50JPY
Average target price
1,503.33JPY
Spread / Average Target
+0.66%
Consensus

Quarterly revenue - Rate of surprise